SGP – The first patient has been dosed in the phase-3 Boceprevir trials. <a href="http://sec.gov/Archives/edgar/data/310158/000095012308011241/y71419exv99w1.htm" target="_blank">http://sec.gov/Archives/edgar/data/310158/000095012308011241/y71419exv99w1.htm</a>